Cargando…

Tislelizumab combined with anlotinib in the second-line treatment of malignant pleural mesothelioma

Malignant pleural mesothelioma (MPM) is a malevolent tumor originated from pleura and often leads to poor prognosis. Chemotherapy of pemetrexed and cisplatin combined with antiangiogenic therapy of bevacizumab is recommended as the first-line regimen by guidelines. However, there are few sustainable...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Dandan, Liang, Jianping, Lv, Yanhua, Huang, Xikun, Guo, Weihong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803428/ https://www.ncbi.nlm.nih.gov/pubmed/36596035 http://dx.doi.org/10.1097/MD.0000000000032459

Ejemplares similares

Pemetrexed Maintenance Therapy Following Bevacizumab-Containing First-Line Chemotherapy in Advanced Malignant Pleural Mesothelioma: A Case Report and Literatures Review
por: Jing, Xu-Quan, et al.
Publicado: (2016)

Advanced intrahepatic cholangiocarcinoma treated using anlotinib and microwave ablation: A case report
por: Zhang, Aixia, et al.
Publicado: (2019)

Carrelizumab combined with anlotinib in the treatment of extensive-stage small cell lung cancer: A case report
por: Liu, Liang, et al.
Publicado: (2021)

Diagnostic value of pleural fluid SMRP, CA125, MMP-7, and MMP-9 in malignant pleural effusion
por: Han, Gaohua, et al.
Publicado: (2023)

Combination use of paclitaxel and avastin enhances treatment effect for the NSCLC patients with malignant pleural effusion
por: Qi, Nan, et al.
Publicado: (2016)

Predictive value of microvascular density for response to anlotinib in advanced NSCLC
por: Liu, Danqing, et al.
Publicado: (2022)

Comprehensive bioinformatics analysis of the role of VWF in the tumor microenvironment of malignant mesothelioma
por: Weng, Jiren, et al.
Publicado: (2023)

Apatinib combined with S-1 as second-line therapy in advanced gastric cancer
por: Qiu, Zhi-Yuan, et al.
Publicado: (2021)

Endostar combined with chemotherapy in a pediatric osteosarcoma with pulmonary metastasis and malignant pleural effusion: A case report
por: Jiang, Sujing, et al.
Publicado: (2017)

Effect and safety of anlotinib combined with S-1 for recurrent or metastatic esophageal cancer patients who refused or were intolerant to intravenous chemotherapy
por: Cai, Jing, et al.
Publicado: (2021)

Orbital adenoid cystic carcinoma treated by radiotherapy combined with anlotinib in a 13-year-old girl: A case report
por: Wu, Xue, et al.
Publicado: (2023)

Esophago-tracheobronchial fistula following treatment of anlotinib in advanced squamous cell lung cancer: Two case reports
por: Zhang, Pin-Liang, et al.
Publicado: (2019)

Durable response of tislelizumab plus cisplatin, nab-paclitaxel followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A case report
por: Tang, Haifeng, et al.
Publicado: (2023)

A case report of immune checkpoint inhibitor nivolumab combined with anti-angiogenesis agent anlotinib for advanced esophageal squamous cell carcinoma
por: Tang, Yong, et al.
Publicado: (2019)

Efficacy and safety of endostar combined with cisplatin in treatment of non-small cell lung cancer with malignant pleural effusion: A meta-analysis
por: Hu, Yongqi, et al.
Publicado: (2022)

Anlotinib, a novel TKI, as a third-line or further-line treatment in patients with advanced non-small cell lung cancer in China: A systemic review and meta-analysis of its efficacy and safety
por: Ye, Haiyong, et al.
Publicado: (2021)

Better survival and prognosis in SCLC survivors after combined second primary malignancies: A SEER database-based study
por: Wang, Silin, et al.
Publicado: (2023)

Late-stage esophageal neuroendocrine carcinoma in a patient treated with tislelizumab combined with anlotinib: a case report
por: Zhang, Yanqi, et al.
Publicado: (2023)

The combination of cisplatin and topotecan as a second-line treatment for patients with advanced/recurrent uterine cervix cancer
por: Moon, Ji Young, et al.
Publicado: (2018)

Efficacy of cisplatin combined with vinorelbine as second- or higher-line palliative chemotherapy in patients with advanced ovarian cancer
por: Yeon, Sang Hoon, et al.
Publicado: (2023)

Pretreatment elevated serum lactate dehydrogenase as a significant prognostic factor in malignant mesothelioma: A meta-analysis
por: Zhuo, Yi, et al.
Publicado: (2016)

Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib
por: Guo, Weihong, et al.
Publicado: (2022)

Efficacy of cisplatin combined with topotecan in patients with advanced or recurrent ovarian cancer as second- or higher-line palliative chemotherapy
por: Lee, Myung-Won, et al.
Publicado: (2020)

Malignant pleural mesothelioma
por: Rao, Sukhesh
Publicado: (2009)

First-line pemetrexed and carboplatin plus anlotinib for epidermal growth factor receptor wild-type and anaplastic lymphoma kinase-negative lung adenocarcinoma with brain metastasis: A case report and review of the literature
por: Zhang, Chu, et al.
Publicado: (2020)

Whole exome sequencing of independent lung adenocarcinoma, lung squamous cell carcinoma, and malignant peritoneal mesothelioma: A case report
por: Vanni, Irene, et al.
Publicado: (2016)

Characteristics and outcomes of primary pleural angiosarcoma: A retrospective study of 43 published cases
por: Wang, Xia, et al.
Publicado: (2022)

Treatment of Metastatic Primary Extramammary Paget Disease With Combination Anlotinib and Tislelizumab: A Case Report and Review of the Literature
por: Yin, Xin, et al.
Publicado: (2022)

Case report: Significant benefits of tislelizumab combined with anlotinib in first-line treatment of metastatic renal pelvic urothelial carcinoma with sarcomatoid carcinoma differentiation
por: Zhu, Shibin, et al.
Publicado: (2022)

Pleural small cell carcinoma with massive pleural effusion: A case report
por: Jang, Jong Geol, et al.
Publicado: (2019)

Comparison between different treatment regimens of vascular targeting drug to malignant pleural effusion in patients with lung cancer: A Bayesian network meta-analysis
por: Huang, Peng, et al.
Publicado: (2023)

Second primary malignancy in patients with esophageal adenocarcinoma and squamous cell carcinoma
por: Zhang, Guoqing, et al.
Publicado: (2019)

The clinical efficacy of traditional Chinese medicine in the treatment of malignant pleural effusion: A protocol of systematic review and meta-analysis
por: Lin, Zhen, et al.
Publicado: (2020)

Salvage anlotinib showed sustained efficacy in heavily pretreated EGFR wild-type lung adenocarcinoma: A case report and review of the literature
por: Liu, Lei, et al.
Publicado: (2020)

Clinical outcome in lung cancer with a second malignancy: The time sequence matters
por: Lu, Ming-Shian, et al.
Publicado: (2016)

Primary pleural epithelioid angiosarcoma treated successfully with anti-PD-1 therapy: A rare case report
por: Wang, Xia, et al.
Publicado: (2021)

Malignant pleural mesothelioma with resolution of pleural effusion
por: Nishida, Sayaka, et al.
Publicado: (2023)

Malignant pleural mesothelioma in Italy
por: Bianchi, Claudio, et al.
Publicado: (2009)

Heterogeneity in Malignant Pleural Mesothelioma
por: Oehl, Kathrin, et al.
Publicado: (2018)

Immunotherapy in Malignant Pleural Mesothelioma
por: de Gooijer, Cornedine J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_r5j6kvdvpat2c3cqmteq0cqio9